skip to Main Content

Ontario Government, University of Toronto, and MaRS secure Johnson & Johnson Innovation, JLABS for Toronto – first JLABS Incubator outside of United States

Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI’s 15 member institutions

 Minister of Economic Development, Employment and Infrastructure Brad Duguid announces the arrival of JLABS @ Toronto in the MaRS Discovery District. First row, left to right: Chris Halyk, president of Janssen Inc.; Melinda Richter, head of JLABS, Johnson & Johnson; Dr. Meric Gertler, president, University of Toronto; Minister Duguid; Dr. Ilse Treuricht, CEO MaRS Discovery District; Dr. Raphael (Rafi) Hofstein, president and CEO MaRS Innovation, and Robert Urban, head of Johnson & Johnson Innovation Boston. Second row: Dr. Robert Howard, president and CEO St. Michael's Hospital; Dr. Catherine Zahn, president and CEO CAMH; Dr. Barry McLellan, president and CEO Sunnybrook Health Sciences Centre; Dr. Peter Pisters, president & CEO University Health Network; Dr. Jim Woddgett, director of research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and Dr. Michael Apkon, president and CEO, The Hospital for Sick Children.

Minister of Economic Development, Employment and Infrastructure Brad Duguid announces the arrival of JLABS @ Toronto in the MaRS Discovery District. First row, left to right: Chris Halyk, president of Janssen Inc.; Melinda Richter, head of JLABS, Johnson & Johnson; Dr. Meric Gertler, president, University of Toronto; Minister Duguid; Dr. Ilse Treuricht, CEO MaRS Discovery District; Dr. Raphael (Rafi) Hofstein, president and CEO MaRS Innovation, and Robert Urban, head of Johnson & Johnson Innovation Boston. Second row: Dr. Robert Howard, president and CEO St. Michael’s Hospital; Dr. Catherine Zahn, president and CEO CAMH; Dr. Barry McLellan, president and CEO Sunnybrook Health Sciences Centre; Dr. Peter Pisters, president & CEO University Health Network; Dr. Jim Woddgett, director of research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and Dr. Michael Apkon, president and CEO, The Hospital for Sick Children.

 

TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto.

This announcement has been covered in the Toronto Star, Metro News Canada, Sing Tao Daily, OurWindsor.ca, FierceBiotech, BioCentury, MedCity News, BioSpace, Biotechnology Focus, Lab Product News, ChinaNews.com, Pan European Networks, Economic Development Blog, BetaKit, Torontoist, and TechVibes.

It was also featured news on Rx&D‘s and Life Sciences Ontario‘s websites.

The new facility, called JLABS @ Toronto, will open in spring of 2016 at MaRS Discovery District and will support start-ups with lab space, programs, and potential investment partners as they work to build important, successful early-stage companies.

“The arrival of the Johnson & Johnson Innovation, JLABS model to MaRS’ West Tower reinforces Ontario’s position as one of the world’s leading life sciences clusters,” said Brad Duguid, Minister of Economic Development, Employment and Infrastructure. “JLABS @ Toronto will support researchers and entrepreneurs across the province and accelerate the development of Ontario companies while connecting Toronto to potential Johnson & Johnson collaborators and investors.”

“Research and innovation are fundamental to the mission of the University of Toronto,” said Dr. Meric S. Gertler, President, University of Toronto. “We host a vibrant entrepreneurial ecosystem featuring nine campus-led accelerators under the umbrella of our Banting & Best Centre for Innovation and Entrepreneurship. The addition of JLABS to this ecosystem will further propel the creation of new companies and new jobs, and ultimately new healthcare solutions that will benefit individuals and our society for years to come.”

“Toronto is home to a vibrant and prolific healthcare and life sciences community led by academic hospitals, world-class research institutions, top scientists, and a strong start-up ecosystem. For these reasons, Toronto is a natural choice for our first international expansion of JLABS,” said Melinda Richter, Head of JLABS. “The Johnson & Johnson Family of Companies has long been active within the Toronto Ontario community, forming many important collaborations. Today we are pleased to begin an even deeper relationship with this important community. Our new location, within a University of Toronto site, close to our hospital collaborators, and neighbouring the financial centre of Canada, will deliver great opportunities and impact for emerging biomedical technology entrepreneurs.”

Continue Reading
Back To Top